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ClonotypesRheumatoid arthritis (RA) is characterized by chronic joint inflammation and associates with HLA-DRB1*04. The
Collagen IIp261-273-specific T cell repertoire in the peripheral blood of DR4+ patients at the onset of the disease
shows a restricted TCR-beta chain usage among which the most frequent is TRBV25.
To definewhether this group of DR4-restricted collagen-specific shared T cell could represent markers of active-
severe disease and response to therapy, 90 subjects affected by early-RA were enrolled in the study; peripheral
bloodmononuclear cells were culturedwith orwithout the human collagen II peptide p261-273 andwere exam-
ined by immunoscope analysis for the usage of the previously identified shared TCR-beta chains.
We report that the presence of T cells carrying rearrangement TRBV25 associated with HLA-DR haplotype and
disease activity. HLA-DRB1* haplotypes 04–04, 04–01 and 04–11 were significantly associated with usage of
TRBV25, higher disease activity at the onset of disease and poor response to DMARDs.
Finally, theHLA-DRB1* haplotype appeared complementarywith current serologic tools to predict good andpoor
responders in a treat to target strategy. The data reported here offer clues to predict the course of the disease and
to foresee personalized treatments in RA patients.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Rheumatoid Arthritis (RA) is an autoimmune disease and a systemic
inflammatory disorder affecting joints and internal organs. It is one of
the main causes of disability in the western world. The etiology and
the triggers of autoimmunity and in particular of RA have been ascribed
to different factors: genetic and environment. The humoral and cell-
mediated immune responses inwhich self-reactivity plays an important
role are key points in the pathophysiology of RA. The chronic synovialti-cyclic citrullinated peptide an-
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. This is an open access article underinflammation involved in joint destruction and disability is mediated
by the infiltration of the activated immune cells: CD4+ T cells, B cells,
dendritic cells and macrophages (Cooles and Isaacs, 2011; van der
Woude et al., 2010; Willemze et al., 2012; Michelutti et al., 2011;
Tolusso et al., 2009).
Family-based and twin-based studies have shown that the heritabil-
ity of RA accounts for about 60% of the developmental risk, one third of
which has been linked to two particular major histocompatibility anti-
gens (human leukocyte antigens) namely HLA-DRB1*04 and 01
(Deighton et al., 1989). The genome-wide association studies (GWAS)
and meta-analyses identified and combined a number of single nucleo-
tide polymorphisms (SNPs) related to RA, both in HLA and non-HLA
genes (Chatzikyriakidou et al., 2013;Mesko et al., 2010). Several studies
about the amino-acids motifs at the position 70–74 of the third hyper-
variable region of HLA-DRB1molecules associated not onlywith RA sus-
ceptibility (RR-QK-QRRAA as in DRB1*0101, *0102, *0401, *0404, *0405,
*0408, *0410, *1001 and *1402) or protection (DERAA as in *0103,
*0402, *1102, *1103, *1301, *1302 and *1304) (Feitsma et al., 2008),
but also to disease severity and progression (Gonzalez-Gay et al.,
2002) with variations among different ethnicities and populations,
also demonstrated in Kapitany et al. (Kapitany et al., 2005).
The response to (self or non-self) antigens restricted by similar class II
MHCmolecules leads to a usage of a limited number of rearrangements ofthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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variable-diversity-junctional segments (V-D-J) and similar three-
dimensional structures of the third complementarity-determining region
(CDR3). Many studies have shown that in RA patients the TCR repertoire
is skewed to certain BV genes, suggesting oligoclonal expansions
(VanderBorght et al., 2000; Li et al., 1994; Wagner et al., 1998) and phe-
notype alterations responsible of autoreactivity, immunosenescence and
a proinflammatory state of CD4+ T lymphocytes (Spurlock et al., 2015).
Such TCR repertoire remains stable during the disease, in part due to cen-
tral tolerance that reduces the potentially self-reactive repertoire, and in
part for competition between memory and naïve T cells in the lymph
nodes for the antigen presentation (Lanzavecchia and Sallusto, 2002).
Epitope encompassing residues 261–273 of type II human Collagen
(CII261-273) is thedominant antigenic epitope of Type II Collagen restrict-
ed by HLA DRB1*04 and HLA DRB1*01, as supported also by the obser-
vation that it is the dominant epitope for the T cell response during
collagen-induced arthritis (CIA) in mice transgenic for the human HLA
DRB1*01 and DRB1*04 in mice (He et al., 2004). Other studies demon-
strated that the use of an altered peptide CII261-273 inhibits T cell activa-
tion in CIA inducedmice (Zhao et al., 2008; Li et al., 2006), and that T cell
reactivity to the peptide 264–270 correlates with disease activity in a
cohort of DRB1*04 RA patients (Snir et al., 2012). Even though it has
not been clarified if CII-specific T cells are involved in the pathogenesis
of early RA or if they are a consequence of joint damage, the status or the
size of the autoreactive T cell repertoire appears to bemodulated by the
level of both unmodified and glycosylated Collagen II peptides
(Backlund et al., 2002).
In a previous work (Ria et al., 2008) we performed a complete anal-
ysis of CDR3 length distribution of the TCR Vbeta-chain of T cells specif-
ically expanded by Coll261-273 in HLA DRB1*04+ ERA patients. We
analyzed TCR BV gene usage and clonality of circulating and infiltrating
T cells in the synovial fluid of RA patients using semiquantitative PCRs
and modified BV-BJ immunoscope technique, finding that the reper-
toires of Coll261–273-specific T cells in peripheral blood and synovial
fluid show a restricted variety of rearrangements of the TCR-beta
chain. The TCR-beta chains identified by immunoscope analysis were
sequenced and showed that identical aa sequenced were enriched by
antigen stimulation among patients, and therefore identified a group
of “shared” clonotypic, collagen-specific T cells. T cells carrying
TRBV25-TRBJ2.2 were most frequently used among DR4+ patients
affected by ERA. Finally, the majority of the repertoire was shared be-
tween different patients affected by RA (Ria et al., 2008) with respect
to HLA DRB1*04+ healthy controls. These results were confirmed
through different methods in a small cohort of early and long standing
RA patients, not selected on the basis of the HLA-DR(Zhou et al.,
2014). When we investigated the mechanism of Coll261-273-HLA-
DRB1*04 recognition by TRBV domain using molecular modeling,
protein-protein docking and molecular dynamics simulations, we
could demonstrate that the residues 70–74 shared by HLA-DRB1*01
and HLA-DRB1*04 directly contributes to the engagement of beta
chain of a Coll216-273-specific TCR (De Rosa et al., 2010).
In the present work, we aimed to define the association of the anti-
gen specific T cell receptorwith DR alleles, with disease activity-severity
and with response to conventional DMARDs. The results show that the
TRBV25 rearrangement identifies, along with HLA-DRB1, patients with
the most active and refractory RA.
2. Material and Methods
2.1. Patients
A total of 90 patients affected by rheumatoid arthritis (RA) were en-
rolled, with symptoms duration of less than 12 months at diagnosis
(ERA patients). Overall we collected 111 samples, 25 of which from
ERA patients with a high disease activity (DAS ≥3.7), 31 with a DAS
comprised between 3.7 and 2.4, 17 with a DAS between 2.4 and 1.6,and 38 samples from patients during a remission phase (DAS b1.6).
All the recruited samples were prepared for the TCR analysis.
All the RA patients fulfilled the 1987 and 2010 American College of
Rheumatology (ACR) criteria for RA (Arnett et al., 1988; Aletaha et al.,
2010).
At baseline, ERA patients were treated with methotrexate (up to
20 mg weekly) and, when necessary, with a low steroid dosage for
three months; a combination with a TNFα blocker (adalimumab
40mg every twoweeks, or etanercept 50mgweekly) was started if pa-
tients did not reach at least a good response within three months from
the onset of therapy, according to EULAR criteria (DAS44: DAS ≤2.4).
ERA patients were followed every month up to three months and
every three months thereafter. At each visit the ACR European League
Against Rheumatism (EULAR) core data set (erythrocyte sedimentation
rate (ESR), C-reactive protein (CRP), swollen joint count (SJC), tender
joint count (TJC), physician and patient global assessment, pain, health
assessment questionnaire (HAQ))was registered and DASwas calculat-
ed (Fransen and van Riel, 2005).
At each visit, clinical improvement and remissionwere evaluated ac-
cording to DAS (van Gestel et al., 1996; Prevoo et al., 1996). Written in-
formed consent was obtained from all study subjects. This study was
performed according to the Declaration of Helsinki and was approved
by the local ethics committee.2.2. HLA Genotyping
We performed HLA-DRB1 genotyping and CDR3 length analysis in
90 ERA patients enrolled at different time points: 35 at diagnosis (T0),
of which 20 with high disease activity (DAS ≥3.7), 12 with a moderate
disease activity (3,7 N DAS ≥ 2.4) and 3 with low disease activity (DAS
b2.4); the other 55 patients also during the follow up of the disease
(T ≠ 0) reaching a total number of 111 samples (for some patients
more samples were collected at different time points). The mean dis-
ease duration since the enrollment of all the ERA patients was 10.7
months after diagnosis.
Genomic DNA for the HLA genotyping was obtained from whole
blood of the 90 ERA patients using QIAamp DNA Mini kits for genomic
DNA purification (Qiagen GmbH, Hilden, Germany) and 0.05–0.1 μg of
purified gDNA were used for the PCR amplification of exon 2 of HLA-
DRB1.
After PCR amplification molecular typing of HLA-DRB1 by a reverse
hybridization method was performed using the INNO-LiPA HLA-DRB1
plus kit (Innogenetics N. V., Ghent, Belgium) and following
manufacturer's instructions. Interpretation of hybridization of HLA-
DRB1 probes was made by use of LiRAS software, to predict one digit
HLA.2.3. Cell Culture
Peripheral blood mononuclear cells (PBMCs) were purified from
whole blood by Lympholite-H density gradient (CEDARLANE Laborato-
ries Ltd., Burlington, Canada), as described in manufacturer's protocol.
Purified PBMCs were cultured in presence or absence of 20 μg/ml
Coll261-273 for 72 h in RPMI 1640 medium (Sigma Aldrich, St. Louis,
MO, USA) supplemented with 2 millimoles/l L-glutamine, 50 milli-
moles/l of 2-ME (mercaptoethanol), 50 μg/ml of gentamicin (Sigma-Al-
drich, St. Louis, MO, USA), and 1% human AB serum (following the
protocol described in Nicolò et al. (Nicolo et al., 2006) and Ria et al.
(Ria et al., 2008)). Seventy-two hours later cells were harvested and
antigen-specific cell proliferation was assessed by cell count after
Trypan blue staining (Burker chamber). Cell death was shown not to
be different between antigen-stimulated and unstimulated PBMC by
staining for annexin V and Propide Iodide as described in our previous
work (Ria et al., 2008) to avoid any bias.
Table 1
Demographic, immunological and clinical characteristics of ERA patients at di-
agnosis. Values are mean ± standard deviation unless otherwise indicated.
ERA: early rheumatoid arthritis; ACPA: anti-citrullinated peptide antibodies;
RF: rheumatoid factor; ESR: erythrocyte sedimentation rate; CRP: C-reactive
protein; TJC: tender joint count; SJC: swollen joint count; DAS: disease activity
score; HAQ: Health Assessment Questionnaire. HLA: histocompatibility Leuco-
cyte Antigen. ESR, CRP, TJC, SJC, HAQ, are missing in 5 patients.
ERA patients
N. 90
Age, (years) 55.0 ± 13.6
Sex, n° female, (%) 70.0 (77.8)
ACPA N 5 U/ml n. (%) 64 (71.1)
RF-IgM N 20 U/ml n. (%) 46 (51.1)
ESR (mm/1 h) 41.9 ± 26.4
CRP (mg/l) 24.9 ± 31.7
TJC 11.6 ± 8.0
SJC 14.7 ± 8.8
DAS 3.8 ± 1.1
HAQ 1.29 ± 0.77
Symptoms' duration (months) 6.27 ± 3.55
HLA-DRB1*01 n. (%) 21 (23.3)
HLA-DRB1*04 n. (%) 27 (30.0)
HLA-DRB1*11 n. (%) 32 (35.6)
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Coll261-273-specific T cells secreting IL-13 and IL-17were stained and
enriched from PBMCs obtained from ERA patients using MACS® secre-
tion kit (Miltenyi Biotec, Germany) according to the manufacturer's in-
struction, following the protocols for enrichment of low-frequency
secreting cells. Briefly, 2 × 107 to 4 × 107 cells obtained from PBMCs
were stimulated in absence (background) or in presence of 10 μg/ml
of Coll261-273 peptide (positive sample), in a 24-well plate at a concen-
tration of 0.5 × 107 cells ml/well. Three hours (for IL13 staining) and
16h (for IL17 staining), cells were harvested and submitted to the stain-
ing procedure for each cytokine. The enrichment for cytokine-secreting
cells was checked by flow cytometry (Coulter Epics FACS, equipped
with Lysis software) (Beckman Coulter Inc., Fullerton, CA, USA) analysis.
In order to evaluate correctly the number of antigen-specific cells, we
examined by FACS 5 × 105 cells both in the background and in positive
samples. Total, negatively selected and positively selected cells were
collected and prepared for mRNA isolation. As previously published
(Nicolo et al., 2006), in order to prevent uncontrolled loss of mRNA
due to scarcity of cells in the positively selected fraction (usually ~104
total cells were recovered in the cytokine-positive fraction), mRNA ob-
tained from 106 TCR alpha-beta-BW cells (a mouse T cell line lacking
the expression of alpha- and beta- chains of the TCR) was added to
the positively selected cells before proceeding with mRNA isolation for
the TCR repertoire analysis.
2.5. TCR Repertoire Analysis
Total mRNA was isolated from cell suspensions using RNeasy
Mini Kit (Qiagen GmbH, Hilden, Germany), in accordance with the
manufacturer's instruction. cDNA was synthesized using an oligo-dT
primer (dT15; Gibco BRL Life Technologies). From each cDNA, PCR reac-
tions were then performed. Sequences of TRBV25, TRBC1alfa and
TRBJ2.2 specific primers were deduced from the IMGT (ImMunoGeneT-
ics, www.imgt.com) and described in Ria et al. (Ria et al., 2008).
Using 2 μl of this product as a template, run-off reactions were per-
formed with a single internal fluorescent primer for each BJ tested.
These products were then denatured in formamide and analyzed on
an Applied Biosystem 3130 Prism using Gene-mapper version 4.0 soft-
ware (Life Technologies, Amsterdam, The Netherlands). Results are
also reported as RSI (rate stimulation index = normalized peak area
obtained from cells stimulated with antigen/normalized peak area of
non-stimulated cells). Analyzing the 90 ERA patients we looked for
TCRs expansions, in particular TRBV25-TRBJ2.2 with the length of 139
bases (alias name vb11-jb2.2, hereafter TRBV25). The cut-off for
positive specific expansions defined as rate stimulation index (RSI)
was settled RSI ≥1.8) and the TCRs sequences, identifying common
variable-diversity-junctional segments (V-D-J), were described in our
previous work (Ria et al., 2008).
We found on a large collection of samples that peaks of length other
than those previously identified as associated with the response to Coll
peptide had a SI of 1 ± 0.34 when ag− versus ag+ were compared.
Thus, we chose the SI value of 1.8 (Naverage + 2SD) as a cut off value
for a specific expansion.
2.6. Statistical Analysis
Data were analyzed using SPSS Statistics 20.0 (IBM Corp., Armonk,
NY, USA) and Prism software 6.01 (Graph-Pad, San Diego, CA 92121-
USA). Categorical and quantitative variables were respectively de-
scribed as numbers, percentages (%) and mean ± standard deviation
(SD). Mann–Whitney's test was used to compare continuous variable.
Categorical variables were analyzed using χ2 test or Fisher's test, de-
pending on sample size restrictions. Kaplan–Meier survival plots were
created using Prism software 6.01 (Graph-Pad, San Diego, CA 92121-
USA). Statistical significance of survival analyses and P-values weredetermined by applying the Log-rank statistical method (Mantel-Cox
test) and the Gehan–Breslow method (Wilcoxon test) taking into ac-
countmultiple comparisons. A value of P b 0.05was considered statisti-
cally significant.
3. Funding
This work was partially supported by “linea D1” from Catholic Uni-
versity of Rome (Gianfranco Ferraccioli and Francesco Ria).
4. Results
4.1. HLA-DRB1 and Disease Activity at Diagnosis: Group Differences
We examined in our cohort whether DR4-4, DR4-11 and DR4-1 pa-
tients represented collectively a subgroup of patients with a more ag-
gressive disease.
A total of 90 ERA patients treated with the treat-to-target strategy
were enrolled. The mean DAS value in the whole ERA cohort was
3.8 ± 1.1 (51.1% with an active disease-DAS ≥3.7, 42.2% with a moder-
ate disease-2.4 b DAS b 3.7 and 6.7% with a low disease activity-DAS
≤2.4). The demographic, immunological and clinical characteristics of
RA patients are shown in Table 1.
The HLA-DRB1 genotyping of ERA patients showed, as expected
(Reveille, 1998; Rosloniec et al., 2002), a high prevalence of HLA
DRB1*04 and *01 positive patients (Supplementary Fig. 1a). The allelic
frequency of DR4 was 18.9% in a total of 27 out 90 ERA patients, of
which 7 (7.8%) were homozygous; moreover, the allelic frequency of
DR1+was 13.3% in a total of 21 subjects, of which 3 (3.3%) were homo-
zygous and 5 (5.6%) were DR4+ DR1+. Finally, the allelic frequency of
DR11 was 18.3% for a total of 32 out 90 ERA patients, of whom 2 (6.3%)
were DR1+DR11+and 4wereDR4+DR11+ (12.5%). (Table 2) Thus,
DR11, despite its protective role in RA, appears to be the second most
frequent allele in this cohort of patients (Supplementary Fig. 1a and
Table 2), and for this reason we decided to examine in depth its associ-
ation to RA.
We did not consider the alleles with a frequency less than 10%
because the low number of cases was not sufficient to do a correct
power analysis. Nevertheless, in our cohort of ERA DR3, DR7, DR8,
DR9, DR10, DR12, DR14, DR15 and DR16 seemed not to be involved in
RA characteristics (severity or outcome). DR13 allele (13.5%) in our co-
hort of RA did not associate with the clinical parameters-data and was
Table 2
HLA-DRB1*01, *04 and *11 alleles. Values report the absolute number of positive subjects and frequency (%) in the 90 ERA patients, for each indicated haplotype.
ERA patients (N = 90)
HLA-DR allele combinations n. (%) HLA-DRB1*01 HLA-DRB1*04 HLA-DRB1*11 Other allele combinations
HLA-DRB1*01 21 (23.3) 3 (3.3) 5 (5.6) 2 (2.2) 11 (12.2)
HLA-DRB1*04 27 (30.0) 5 (5.6) 7 (7.8) 4 (4.4) 11 (12.2)
HLA-DRB1*11 32 (35.6) 2 (2.2) 4 (4.4) - 26 (28.9)
HLA-DRB1*04 + and (04+ or 01 + or 11+) 16 (17.8)
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tive role in RA (Lundstrom et al., 2009).
We examined whether the presence of isolated DR4, DR1 and DR11
had any effect on severity of the disease at diagnosis. Data reported in
Fig. 1a show that the individual presence of each of these DR alleles
per se did not associate with the severity of the disease at diagnosis.
Next,we focused our analysis on the 27DR4+patients only, andwe ob-
served that patients homozygous for HLA-DRB1*04 or carrying HLA-
DRB1*01 or HLA-DRB1*11 as the second allele showed a higher disease
activity at diagnosis when compared to DR4+ patients carrying other
HLA-DRB1 alleles, both when DAS was divided in classes (data not
shown p= 0.03) and when the absolute value of DAS was considered
(Fig. 1b, 4.3 ± 1.4 vs 2.9 ± 0.6, p= 0.002).
4.2. DR Haplotype and Disease Activity Determine the Presence of Circulat-
ing Coll263-271-specific TRBV25+ T Cells
Next, we examined the possible relationship between disease activ-
ity score and the presence and/or level of stimulation index of T cells
carrying the shared TRBV25 rearrangement in DR4+ patients. Patients
were divided in low (n = 11) or moderate-high activity (n = 16) on
the basis of their DAS at the moment of the test. We found expansions
of the huColl261-273 specific TCR rearrangement of interest (TRBV25-
TRBJ2.2 with a length of 139 base pairs) more frequently in patients
with a moderate-high disease activity score than in patients with aFig. 1.HLADRB1 is associatedwith disease severity at the onset in DR4+patients. (A) The
six groups of patients positive or negative for HLA-DRB1* allele 01, 04 and 11 are divided
in 3 classes, based on DAS at onset: DAS ≤2.4 (white), 2.4 b DAS b 3.7 (gray) and DAS ≥3.7
(black). (B) DR4+ patients (N= 27) were divided in two groups on the basis of the sec-
ond DRB1* allele: all the DR4+ patients are shown individually on the basis of DAS at the
onset and on the basis of the presence (black circles) or the absence (white circles) of DR4
orDR1 orDR11 as second allele. Each group is further subdivided, as described for panel A.DAS b2.4. InDR4+ERApatients, DAS seemed to be directly proportion-
al to the absolute value of the RSI (data not shown, p = 0.01) and this
was confirmed by the comparison of the two groups of patients (low
versus moderately-highly active disease) on the basis of positivity (RSI
≥1.8) versus negativity (RSI b1.8) of TRBV25; eleven out of sixteen
(68.8%) patients with a moderate-high disease activity were positive
for TRBV25+ cells versus one out of eleven (9.1%) patients with a DAS
b2.4 (p = 0.0047, exact Fischer's test, Fig. 2a).
Next we examined if the second HLA allele had an influence on the
presence of cells carrying the TRBV25 TCR within the DR4+ group of pa-
tients. Fig. 2b reports the RSI of the TRBV25 rearrangement and the DAS
value for each of the DR4+ patients examined (n= 27), with the differ-
ent symbols representing the second DR allele. Thus, on a total of 11
DR4+ ERA patients that used the collagen-specific TRBV25 rearrange-
ment, we observed that 4 were DR4 + DR11+, 4 were homozygous for
DR4, and 1 was DR4 + DR1+. All these patients were examined when
in high or moderate disease activity. Intriguingly, all DR4 + DR11+ pa-
tients grouped within the samples obtained during moderate-high
disease activity andpositive for TRBV25usage,while somepatients homo-
zygous for DR4 or having DR1 as the second DR allele fell in the group ofFig. 2. TRBV25 usage and DR4 and DR11 aremarkers of disease activity and of response to
“treat to target” strategy. (a) PBMC from 27 consecutive HLA DRB1* 04+ ERA patients at
different phases of disease activity were stimulated with Coll261-273 and considered posi-
tively expanded when rate stimulation index (RSI) of TRBV25 was at least 1.8 or superior.
TheDR4+patients, samples positive for the usage of shared TCR (here represented inper-
centage) are significantly more frequent in subjects with higher DAS. P value is evaluated
with unpaired non-parametric Mann Whitney's test comparing patients on the basis of
TRBV25 positivity and negativity (p = 0,04). (b) Associations between DAS, RSI for
TRBV25+ cells and the second HLADRB1* allele in the 27 DR4+ ERA patients. Vertical
dashed lines indicate DAS of 1.6, 2.4 and 3.7. Symbols indicate patients homozygous for
DR4 (gray circles), or DR4/1 (white circles), DR4/11 (black circles) and finally those in
which DR4 was associated with any other HLA allele (white squares).
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collagen-specific TRBV25 rearrangement. Thus, it appears thatDR11 allele
is able to promote the usage of TRBV25 by DR4+ subjects at least as well
as (and possibly even better than) a second DR4 allele. Finally, the vast
majority (8/11) of DR4+ patients with a low disease activity at the mo-
ment of the test were heterozygous, but having as a second DR allele DRs
different from DR1 or DR11 (Fig. 2b).
Overall, these results, despite the low number of patients, suggest
that the presence of peripheral blood T cells carrying the TRBV25 TCR
specific for Coll261-273 represent a marker of moderate-high disease
activity in RA patients carrying DR4 allele. Moreover, the homozygosity
for DR4 or the combination of DR4with DR1 or, surprisingly, with DR11
seems to be associated with the usage of Coll261-273 specific T cells,
carrying the TRBV25 TCR, andwith increased disease severity and resis-
tance to therapy.
4.3. HLA-DRB1 Haplotype Predicts Response to Therapy in ERA Patients
Sincewe had observed that HLAwas associatedwith disease activity
at the onset andwith selection of a TCR repertoire in theDR4+group of
patients, next we examined the influence of HLA-DR on the therapeutic
outcomeof the patients. Overall, 60 (58.8%) ERApatientswere classified
as good EULAR responders, while 38.8% and 50.6% were in DAS remis-
sion (DAS b1.6) at 6 and 12 months follow-up visit, respectively. Five
ERA patients were lost during follow-up. Results are reported in
Fig. 3a and b. Following the results reported in the above section, we di-
vided patients in 4 groups: Group 1: DR4, DR1 andDR11 triple negative;
Group 2: DR4- and DR1+ or DR11+; Group 3: DR4+ and DR1- orFig. 3.DR1, DR4 andDR11 allele combinations and the outcome of disease activity. (a) ERA patie
therapy and are displayed in 4 groups on the basis of the allelic combinations: 1) DR4, DR1 andD
and DR1- or DR11- (dark gray bars) and 4) DR4 allele in combination with another DR4 or DR1
(DAS reduction ≤ 1.2 left bars) or for the achievement of a DAS value b1.6 (right bars). Patients in
Whitney's test, T6 p = 0.04 (* 4 versus 1, ° 4 versus 2, # 4 versus 3): T12 * p = 0.03 and ° p =
(a) (Group 1, dashed gray; Group 2, dashed black; Group 3, continuous gray; Group 4, contin
N1.2) of the disease, (c) the % of patients not adding biologic treatments and (d) % of patients
Rank (Mantel Cox's test) and ERA patients of group 4 showed a behavior significantly diffe
(c) p = 0.002, but not for time of remission after addition of biologic therapy (d) p = 0.2.DR11-; Group 4: DR4+ in combination with another DR4 or a DR1 or
DR11. Patients belonging to Group 1 and 3 were more frequently good
responders if compared to patients of Group 2 and of Group 4.
DR4+ ERA patients having DR1, DR4 or DR11 as a second allele
received a combination therapy with biologic agents within 12
months follow-up (73.3%). This finding was significantly higher
compared to RA patients of other groups at the same time point of
follow up (nearly 30.0%; p = 0.002) (Fig. 3c and Supplementary
Fig. 2). However, in terms of outcome of the combination therapy
of patients of group 4, compared to that of patients belonging to
the other groups submitted to the same therapeutic regimen, no dif-
ferences could be observed (Fig. 3d).
Taken together, these data indicate that a DR4-4, DR4-1 or DR4-11
genotype marks a group of patients suffering a more active and severe
disease, which appears resistant to DMARDs but responsive to biologic
therapy.
4.4. HLA-DRB1 and Seropositivity for ACPA are Complementary in Identify-
ing the Subsets of Good and Poor Responders
Wewonderedwhether the combination of HLADR alleles associated
with severity of disease was simply highlighting the same population of
RA patients showing presence of anti-cyclic citrullinated peptide anti-
bodies. Thus, we separated our ERA patients cohort into ACPA+ (sero-
positive) and ACPA- (seronegative) and, as done in Fig. 4, divided them
into 4 subsets: Group 1: DR4, DR1 and DR11 triple negative; Group 2:
DR4- and DR1+ or DR11+; Group 3: DR4+ and DR1- or DR11-;
Group 4: DR4+ in combination with another DR4 or a DR1 or DR11.nts are evaluated after six (T6) and twelve (T12)months of follow upduring treat to target
R11 triple negative (white bars), 2) DR4- andDR1+or DR11+ (light gray bars), 3) DR4+
or DR11 (black bars). Patients' outcome is reported using EULAR criteria for good response
group 4 show a significant poorer response to treatment (unpaired non-parametricMann
0.05. (b/c/d) Cumulative Kaplan Meyer plots of the same groups of patients described in
uous black) indicating (b) the % of patients not in remission (DAS b1,6 and DAS variance
not in remission after addition of biologic therapy. The p values were evaluated with Log
rent for time to remission (b) p = 0.03 and for time to addition of biologic treatment
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TRBV25+ T cells are more frequent in the group 4 (6 out 13, black cir-
cles, Fig. 4a and b).Whenwe compared the response to therapy in sero-
positive patients, groups 1 (n = 13), 2 (n = 31) and 3 (n = 9) were
frequently good responders; they could gain an early DAS reduction of
at least 1.2 and a DAS b1.6. ACPA + DR4+ ERA patients with DR4,
DR1 or DR11 as second DR allele (group 4, black line), on the other
hand, presented a poor response to a treat to target strategywith remis-
sion significantly delayed (Fig. 4c) and they were treated significantly
more often with biologic DMARDs therapy (Fig. 4e) than the other
groups. Thus, having a DR4-4, DR4-1 and DR4-11 allele combination
represents a marker of poor response to therapy also when examined
within the ACPA+ group of ERA patients.
ACPA- ERA patients (n= 24) seem to have a different response to a
treat to target strategy, but numbers are too small to predict a signifi-
cantly different outcome (Fig. 4d and f). Overall DR and ACPA appear
complementary tools to identify good and poor responders.
4.5. Cells Carrying TRBV25 can Produce IL-17
We have shown above that the same HLA-DRB1 haplotype predicts
severity of the disease and resistance to treatment and in parallelFig. 4. DR1, DR4 and DR11 allele combinations and the outcome of disease activity in ACPA pos
e) andACPA- (b, d, f) and are divided in the 4 groupsdescribed in Fig. 3, on the basis of the allelic
positivity, DR and RSI of the Coll261-273-specific TRBV25+ T cells (number of patients per group
1B=8, 2B=11, 3B=3, 4B=2). (c to f) Cumulative KaplanMeyer plots of the same groups of
Group 2, dashed black; Group 3, continuous gray; Group 4, continuous black) indicating (c, d) th
of patients not yet adding biologic treatments.Missingpatients for followupdata are 14 for C, 9 f
Cox's test) and patients of Group 4 had a significantly worse outcome than the other groups inusage of TRBV25 collagen-specific T cells, which are also associated
with a more severe outcome of the disease. This observation leads to
the hypothesis that an effect of HLA-DRB1 haplotype is the selection of
collagen specific T cells characterized by higher aggressive behavior.
An important goal to better investigate the role of T cells in RA is the
characterization of their cytokine production, in particular IL17 and
IL13. As a proof of concept here we report two case-reports where we
explored the hypothesis of this connection. We stimulated PBMC from
2 DR4+ ERA active patients with Coll261-273 and sorted the T cells se-
creting IL17 and IL13. We examined the presence of T cells specific for
huColl261-273 using the VB-JB pairs previously shown to host shared
TCR-beta chain rearrangements. The RA patients presented in the
PBMC 7 TCR-beta chains that were expanded by the stimulation with
huColl261-273, among which there were the shared TRBV25 T cells
(CDR3 length of 139 bases and Rate Stimulation Index of 1.8). When
we examined the presence of the same 7 TCR-beta chain rearrange-
ments found in the blood in the IL17-secreting cell population, we
could detect only the TRBV25 TCR chains (Fig. 5a). Thus, the antigen spe-
cific T cells able to secrete IL17 seem to represent a restricted subpopu-
lation within the total T cell repertoire responding to the self-antigen
during the acute presentation of the disease (Fig. 5b). The TRBV25 rear-
rangement was not enriched in the IL-13 secreting population from theitive patients. ERA patients are divided on the basis of the positivity to ACPA (ACPA+, a, c,
combinations. ACPA statuses aremissing in 5 patients. (a and b) Correlation betweenACPA
: ACPA+=66 distributed in 1A= 13, 2A= 31, 3A= 9, 4A= 13; ACPA-= 24 divided in
patients divided according to DR as already described in Fig. 3 (BD) (Group 1, dashed gray;
e % of patients not in remission (DAS b 1,6 andDAS varianceN1.2) of the disease, (e, f) the %
or D and10 for E and F, P values of KaplanMeyer plots are evaluatedwith Log Rank (mantel
the ACPA+ patients: p = 0.01 for c, p b 0.0001 for e.
2043G. Di Sante et al. / EBioMedicine 2 (2015) 2037–2045same patients, nor from PBMC IL17+ or IL13+ T cell populations in two
more patients in low disease activity (data not shown) further suggest-
ing that its presence may be involved in the activity of the disease.
5. Discussion
RA has long been considered an autoimmune disease, in which im-
mune complexes mediate tissue injury (Vaughan, 1973; Johnson et al.,
1973). The failure to correlate disease activity to the levels of autoanti-
bodies and the realization that RA exists in individuals not expressing
RF, suggest that T cell very likely play a major role through T cell-
dependent effector mechanisms and T cell-derived cytokines, released
upon T cell recognition of Ag in the synovial membrane (Ferraccioli
and Zizzo, 2011; Zizzo et al., 2011). Activation of macrophages and sy-
novial fibroblasts causes the formation of a tissue-invasive pannus.
HLA-D, expressed by antigen presenting cells (APCs), hosts in the
peptide-binding groove the antigenic fragments to present to T cell re-
ceptor (TCR) on cognate T cells. The polymorphismsofHLA-Dmolecules
can change the amino-acid side chains of the binding pockets, altering
the TCR-peptide-HLA-D interface. For example the residues at positions
11, 71 and 74 of the HLA-DRB1 chain are associated with the higher RA
susceptibility in HLA-DRB1*0401 and *0404, while the *0402 allele has a
protective role (Gregersen et al., 1987; Taneja et al., 2008; Luckey et al.,
2014).
Our data confirm the link between HLA-DRB1 and RA and in partic-
ular in our cohort of 90 Italian patients as expected a 44 present DR4
and/or a DR1 allele, but the secondmost frequent allele is DR11, despite
in literature it is described as having a protective role in RA. It is not the
first observation of an HLA allele with controversial role: in the case of
HLA-DRB1*13 allele, it has been described an association with increas-
ing risk of RA development when in combination with DRB1*03 and
in ACPA negative patients, and at same time a protecting role in ACPA
positive patients (Lundstrom et al., 2009); similarly DR11 seems to
have a “janus” effect in RA, in particular modulated by the association
with DR4.
A modification of the selection of self-epitopes by simultaneous
presence of two HLA alleles may be one mechanism that explains this
“janus” effects. As demonstrated in other autoimmune models, the
modification of peptide presentation can result in the promotion of pos-
itive selection of pathogenic autoreactive thymocytes and/or in the fail-
ure to trigger their subsequent deletion; moreover protective class II
molecules would select a repertoire of T-cells endowed with decreased
pathogenicity (Luhder et al., 1998). The disease predisposing class II
MHCmolecules have also been suggested to contribute to autoimmune
inflammation by modulating the cytokine production of T lymphocytes
in the peripheral tolerance homeostasis (Mangalam et al., 2013). Pro-
tective class IIMHCs have been proposed to compete against or to inter-
fere with self-antigen presentation for capture of determinants (DengFig. 5. TRBV25+cells are enriched among T cells secreting IL17 after stimulationwith Coll261-273
activity phase (a, DAS=2.6) or low disease activity (b, DAS=1.3)were cultured in presence of
For each patient, the presence of a Coll261-273-driven expansion of T cells was examined after 72
report the distribution of CDR3-beta peaks obtained by Immunoscope analysis of rearrangemen
shared Coll261-273-specific rearrangement. This peak appears enriched only in IL-17 secreting cet al., 1993; Ge et al., 2011). In this context it has been demonstrated
that pathogenic autoreactive TCRs are “MHC-promiscuous” (Schmidt
et al., 1997), evidence derived from the fact that individual TCRs have
the inherent potential to recognize a wide set of peptides embedded
in a single MHC molecule or multiple MHC molecules presenting the
same or different peptides (Wooldridge et al., 2012; Brock et al., 1996).
A further role of the protective class IImolecules in autoimmune dis-
ease resistance could be related to the modulation of T regulatory cells
against the self-reactions (Tsai and Santamaria, 2013).
The restriction of the TCR and the sharing of T cells among different
Germinal Centers strongly support a role for few antigens driving the
formation of tertiary lymphoid tissue and subsequent tissue destruction
in the rheumatoid joint (Tsai and Santamaria, 2013).
These antigens are obviously shared among patients because the fol-
licular CD4T cell clones undergo stimulation in the autologous aswell as
in the heterologous tissues. The restriction to HLA-DRB1molecules is in
line with the recognition of classical peptide antigens.
In the present report, we demonstrate that the already known bio-
marker of severity DRB1 (it associates with seropositivity and erosions)
also associates with circulating T cells specific for Coll261-273. These
cells using the shared TCR-beta chains TRBV25-TRBJ2.2 (alias VB11-
BJ2.2) are significantly associated with disease activity in the group of
DR4+ RA patients, and with a worse outcome. The relevance of the
antigen-specific T helper cells has been recently confirmed and their
analysis could represent a new possible approach in the evaluation of
RA (Shoda et al., 2015). Furthermore it has been demonstrated that
HLA-DRB1*04 contributes to RA risk, specifically in CD4+ T cells, with
a cognate and continuous stimulation of TCR-CD3 complexes that cul-
minates in intracellular signaling able to increase the NF-κB activity
and to promote a proinflammatory state (Spurlock et al., 2015). Thus,
we propose that the usage of this T cell receptor is able to predict
the outcome of the disease in DR4+ patients (Ferraccioli and Zizzo,
2011; Raza et al., 2005; Annunziato et al., 2009) and even if it
seems to involve a portion of RA patients, we show here that this
subgroup presents a delayed remission. Probably one of the main
reasons is that DMARDs therapy after diagnosis, as indicated by the
treat to target strategy, is insufficient and only biological treatment
is useful for them; in this sense a TCR specificity in combination
with HLA appears to lead to a more aggressive therapy since the
beginning.
Previous works from other groups have demonstrated that homozy-
gosity for alleles of the DR predisposes to RA severity (Lundstrom et al.,
2009). Here we confirm this observation and report for the first time
that also heterozygosity for DR4-DR1 and DR4-DR11 associate with a
more severe disease. Interestingly, this role of DR11 as a predictor of
worse disease is limited to the DR4+ and ACPA positive RA patients,
while no effect of DR11 per se could be observed in the whole cohort
of RA patients.during active presentation of disease. PBMC fromDR4+patients duringmoderate disease
Coll261-273 andmagnetically sorted for secretion of IL17 (left panels) or IL13 (right panels).
h of culture in the absence or presence of the peptide antigen (middle panels). All panels
t TRBV25-TRBJ2.2. The black peak corresponds to the length of 139 bases that identifies the
ells obtained from the patient in a moderate disease activity phase (a).
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homozygosity for DR4, are associated with the presence of TRBV25-
TRBJ2.2+, collagen-specific T cells during the acute presentation of
the disease. As a proof of concept of our hypothesis we show here that
TRBV25-TRBJ2.2+ T cells likely secrete IL-17, thus contributing to the
aggressiveness of the disease (Leipe et al., 2010; Hot and Miossec,
2011). Thus, these data suggest that these allelic combinationsmay pro-
mote the selection of T cells primed for the collagen-specific self-
reactive response and with possible polarization to a milieu much
more inflammatory (Nicolo et al., 2006).
6. Conclusions
In the present work, we hypothesize that autoreactive T cells, could
be selected on the backgroundof DR4-DR1-DR11 as secondalleles in the
DR4+ RA patients (enhancing the differentiation of autoreactive T
cells) leading to detect the subgroup of patients with amore severe pre-
sentation of RA and amarked resistance to DMARDs. The analysis of the
HLA-DRB1 (determination of the HLA DRB1* is a test available in most
hospital centers) and of T cells specific for Coll261-273 carrying the shared
TRBV25-TRBJ2.2 rearrangement can be proposed as a possible biomarker
matrix that identify those RA patients who will not satisfactorily re-
spond to treatment following a treat to target strategy with TNFα
blockers.
Prospective studies stratifying the patients at diagnosis will be nec-
essary. We are aware of the limits of our cohort, diverse numbers in
different subsets, heterogeneity of the genetic background, different
therapies at follow-up, yet all the data move into the same direction:
our study shows that the analysis of collagen specific the T cell reper-
toire, of HLA-DR and seropositivity appear complementary tools to
identify the best and the poorest responders to DMARD therapy in a
treat to target strategy. Therefore the study offers some clues to predict
the course in terms of a personalized treatment in RA patients (Isaacs
and Ferraccioli, 2011).
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ebiom.2015.11.019.
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